Severe Pregnancy Complications Are Associated With Elevated Factor VIII Plasma Activity
Recruitment status was Active, not recruiting
Congenital and acquired thrombophilia were identified as risk factors for thrombosis in systemic vessels.Thrombophilias have also been recently found to be associated with preeclampsia, intrauterine fetal growth restriction (IUGR), placental abruption, intrauterine fetal death (IUFD) and repeated pregnancy loss.These severe pregnancy complications are thought to result from thrombotic events occurring in the uteroplacental circulation. Accumulating data have established an association between elevated plasma activity of factor VIII and thrombosis although the mechanism is still not defined and elevated factor VIII activity is now regarded as being equivalent to thrombophilia.
We intend to investigatthe association between factor VIII levels and severe pregnancy complications which are considered to result from placental vascular pathology, i.e., preeclampsia, IUGR, placental abruption and IUFD. We hypothezise that the prevalence of elevated factor 8 will be higher among women with pregnancy complications compared to controls.
Intrauterine Fetal Growth Restriction
Intrauterine Fetal Death
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||A Retrospective Analysis of Possible Association Between Severe Pregnancy Complications and Elevated Factor VIII Plasma Activity.|
- prevalenc of elevated factor VIII [ Time Frame: RETROSPECTIVE ] [ Designated as safety issue: No ]
|Study Start Date:||January 2000|
|Estimated Study Completion Date:||January 2008|
The study group included 49 patients with a previous history of one or more of the following pregnancy complications: preeclampsia (n = 17), severe IUGR (n = 13), IUFD (n = 14) or placental abruption (n = 5).
The control group included 49 healthy women who delivered during the study period, who did not smoke during pregnancy and in whom pregnancy and delivery were uneventful
Please refer to this study by its ClinicalTrials.gov identifier: NCT00573118
|Tel Avis sourasky medical center|
|Tel Aviv, Israel, 64239|
|Principal Investigator:||Eli Rimon, MD||Tel Aviv medical center,Israel|